Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Diabetes Dialogue: Semaglutide for MASH in ESSENCE Trial, With Arun Sanyal, MD
Video Version Only on HCPLive!In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new Phase 3 data from the ESSENCE trial examining semaglutide 2.4 mg (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) with…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.